Rchr
J-GLOBAL ID：200901022350771168   Update date: Apr. 11, 2024

Yasui Hiroshi

ヤスイ ヒロシ | Yasui Hiroshi
Affiliation and department：
St. Marianna University School of Medicine Division of Hematology & Oncology, Department of Internal Medicine

About St. Marianna University School of Medicine Division of Hematology & Oncology, Department of Internal Medicine


Job title： Specially Appointed Professor
Other affiliations (3)：
  • The University of Tokyo  Division of Cell Signaling and Molecular Medicine, The Institute of Medical Science   Visiting Associate Professor
  • The University of Tokyo  Department of Hematology/Oncology, The Institute of Medical Science Research Hospital,    Visiting senior assistant professor
  • Mitsui Memorial Hospital  Department of Hematology   A part-time physician
Homepage URL  (1)： https://www.marianna-u.ac.jp/houjin/staff/doctors/yasui_hiroshi.html
Research field  (5)： Hematology and oncology ,  Tumor diagnostics and therapeutics ,  Pharmaceuticals - chemistry and drug development ,  Molecular biology ,  Genomics
Research keywords  (10)： hematology/oncology ,  oncology ,  internal medicine ,  Multiple Myeloma ,  Translational Research ,  Cancer Immunology ,  Investigator initiated trial under IND ,  臨床試験 ,  Genomic Medicine ,  Artificial Intelligence
Research theme for competitive and other funds  (13)：
  • 2022 - 2028 Platform of Supporting Cohort Study and Biospecimen Analysis
  • 2020 - 2023 造血器腫瘍治療における細胞内シグナル修飾と免疫賦活化の両面からの難治性の克服
  • 2016 - 2021 Platform of Supporting Cohort Study and Biospecimen Analysis
  • 2014 - 2016 A fundamental study to develop novel targeted drug delivery systems for multiple myeloma therapy
  • 2010 - 2016 Scientific Support Programs for Cancer Research Grant-in-Aid for Scientific Research on Innovative Areas
Show all
Papers (93)：
  • Naoki Osada, Jiro Kikuchi, Hidekatsu Iha, Hiroshi Yasui, Sho Ikeda, Naoto Takahashi, Yusuke Furukawa. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clinical and Translational Medicine. 2023. 13. 8
  • Jiro Kikuchi, Nobuyuki Kodama, Masataka Takeshita, Sho Ikeda, Takahiro Kobayashi, Yoshiaki Kuroda, Michihiro Uchiyama, Naoki Osada, Bjarne Bogen, Hiroshi Yasui, et al. EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood advances. 2023. 7. 4. 508-524
  • 大貝 明日香, 川俣 豊隆, 佐藤 亜紀, 横山 和明, 小川 弥穂, 櫻井 健一, 磯部 優理, 加藤 せい子, 小沼 貴晶, 安井 寛, et al. 全身性肥満細胞症に合併した急性骨髄性白血病の1例. 臨床血液. 2022. 63. 10. 1461-1461
  • Rui Yamaguchi, Hiroshi Yasui. [A Future Perspective on Cancer Precision Medicine Accelerated by AI and Data Science]. Gan to kagaku ryoho. Cancer & chemotherapy. 2021. 48. 12. 1415-1419
  • Naoki Osada, Jiro Kikuchi, Daisuke Koyama, Yoshiaki Kuroda, Hiroshi Yasui, Joel D Leverson, Yusuke Furukawa. mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3-and Blimp-1-mediated BCL-2 up-regulation. Haematologica. 2021. 106. 11. 3008-3013
ｍore...
MISC (305)：
  • 安井寛, 安井寛, 安井寛, 安井寛. Advances in the biology of multiple myeloma. 月刊血液内科. 2023. 86. 5. 591-595
  • 長田 直希, 菊池 次郎, 安井 寛, 池田 翔, 松岡 紗恵, 高橋 直人, 古川 雄祐. c-FOSはIKZF1転写活性化複合体の重要な構成要素であり、多発性骨髄腫におけるレナリドマイド耐性を誘導する(c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma). International Journal of Myeloma. 2023. 13. 3. 136-136
  • 伏屋 愛加, 上村 悠, 神野 正敏, 安井 寛, 中島 香緒里, 鈴木 黎, 鈴木 義則, 富田 直人, 加藤 雅之, 佐野 文明, et al. アザシチジン・ベネトクラクス療法が奏効した皮下腫瘤合併急性骨髄単球性白血病. 臨床血液. 2023. 64. 4. 305-305
  • 伏屋 愛加, 上村 悠, 神野 正敏, 安井 寛, 中島 香緒里, 鈴木 黎, 鈴木 義則, 富田 直人, 加藤 雅之, 佐野 文明, et al. アザシチジン・ベネトクラクス療法が奏効した皮下腫瘤合併急性骨髄単球性白血病. 臨床血液. 2023. 64. 4. 305-305
  • 越智 清純, 森田 麻衣子, 安井 寛, 山崎 聡. 造血幹細胞の体外増幅プラットフォームを用いた前処置を必要としない骨髄キメラマウス作製法(A versatile platform for generating non-conditioned bone marrow chimeric mice). 日本癌学会総会記事. 2022. 81回. P-2024
ｍore...
Books (8)：
  • ライフライン21 がんの先進医療 別冊 免疫力が変える がんの治療・再発予防効果: 次世代がん治療として世界が注目する免疫療法について、専門家16人が語る最新ガイド
    株式会社 蕗書房 2015
  • 造血器腫瘍とエピジェティクス-治療への応用と新たな展開-
    医薬ジャーナル社 2012
  • 原発性マクログロブリン血症の診断と治療
    多発性骨髄腫診療ハンドブック(中外医学社) 2008
  • プロテアソーム阻害剤ボルテゾミブの臨床応用
    蛋白質核酸酵素 増刊号「ユビキチンープロテアソーム系とオートファジー」 (共立出版) 2006
  • Inhibition of TGF-β signaling in multiple myeloma and its bone marrow microenvironment [Review]
    Transforming growth factor-beta in cancer therapy: Methods in Molecular Biology 2006
ｍore...
Lectures and oral presentations  (33)：
  • 多発性骨髄腫における新規治療薬の有効性と有害事象-日欧米比較研究からの検討-
    (第62回日本体質医学会総会 2012)
  • Study of FLC and PIC in immunoglobulin light chain amyloidosis
    (The 74th Annual Meeting of the Japanese Society of Hematology 2012)
  • A model of Translational Cancer Research in Multiple Myeloma
    (71st Annual Meeting of Japanese Cancer Association 2012)
  • 多発性骨髄腫における基礎研究の進歩と臨床応用
    (第54回日本血液学会秋季北海道地方会 2012)
  • 北海道地域におけるHIV感染症の現況と対策
    (第3回日本プライマリ・ケア連合学会学術大会 2012)
ｍore...
Education (2)：
  • 2000 - 2004 Graduate School of Medicine, Sapporo Medical University
  • 1993 - 1999 Sapporo Medical University School of Medicine
Professional career (2)：
  • Ph.D. (Sapporo Medical University)
  • M.D. (Sapporo Medical University)
Work history (18)：
  • 2024/04 - 現在 St. Marianna University School of Medicine Division of Hematology & Oncology, Department of Internal Medicine Specially Appointed Professor
  • 2024/04 - 現在 The University of Tokyo Division of Cell Signaling and Molecular Medicine, The Institute of Medical Science Visiting Associate Professor
  • 2024/04 - 現在 The University of Tokyo The Institute of Medical Science Research Hospital, Department of Hematology/Oncology Guest senior assistant professor
  • 2018/07 - 現在 Mitsui Memorial Hospital, Tokyo Department of Hematology Visiting Physician
  • 2023/06 - 2024/03 St.Marianna University School of Medicine Division of Hematology and Oncology, Department of Internal Medicine Part-time Lecturer
Show all
Committee career (9)：
  • 2020/09 - 現在 Japanese Society of Myeloma Committee member (publicity, education, review, home page)
  • 2018/04 - 現在 Japanese Electrophoresis Society Director
  • 2016/04 - 現在 Japanese Electrophoresis Society Editorial board, Board of education
  • 2015/10 - 現在 Japan Society for Moleculer Tumor Marker Research Delegate
  • 2015/01 - 現在 The Japanese Cancer Association Councilor
Show all
Awards (5)：
  • 2024/03 - Korean Society of Hematology Best oral presentation award Immune function of chimeric antigen receptor T cells quantitatively assessed via molecular imaging flow cytometry
  • 2019/07 - Japanese Electrophoresis Society Kodama Prize Electrophoresis for advanced clinical medicine of hematologic malignancies
  • 2012/06 - Japan Society of Hematology 17th EHA Congress Travel Award for JSH Young Hematologists
  • 2011/11 - the Japanese Electrophoresis Society Incentive Award for International Conference
  • 2010/11 - International Myeloma Foundation JAPAN The Award in Aki's Memory
Association Membership(s) (18)：
JAPAN PRIMARY CARE ASSOCIATION ,  Japan Society for Moleculer Tumor Marker Reseach ,  THE JAPAN SOCIETY OF HUMAN GENETICS ,  Japan Society of Clinical Trials and Research ,  The Japanese Association of Pharmaceutical Medicine ,  Japanese Association of Cancer Immunology ,  The Japan Society for Hematopoietic Cell Transplantation ,  The Japanese Society of HTLV-1 and Associated Diseases ,  THE JAPANESE SOCIETY OF CLINICAL PHARMACOLOGY AND THERAPEUTICS ,  SOCIETY FOR REGULATORY SCIENCE OF MEDICAL PRODUCTS ,  THE JAPAN SOCIETY OF DRUG DELIVERY SYSTEM ,  JAPANESE ELECTROPHORESIS SOCIETY ,  The Japanese Society for AIDS Research ,  Japan Society of Myeloma ,  Japanese Cancer Association ,  The Japanese Society of Hematology ,  American Society of Hematology ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM